PHVS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.613

-4.18%

-0.641

-24.61%

-0.664

-20.02%

Estimates Revision

Stock Price

Go Up

+13.35%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is 36.86 USD with a low forecast of 27.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

27.00

Averages

36.86

High

60.00

Current: 0.000

Low

27.00

Averages

36.86

High

60.00

Leerink

Outperform

upgrade

$28 -> $38

2025-12-03

Reason

Leerink

Price Target

$28 -> $38

2025-12-03

upgrade

Outperform

Reason

Leerink raised the firm's price target on Pharvaris to $38 from $28 and keeps an Outperform rating on the shares following the disclosure of the company's positive topline data from the RAPIDe-3 study. This morning, Pharvaris reported overwhelmingly positive results from the Phase 3 RAPIDe-3 study, which explored deucrictibant, an oral small-molecule antagonist of the bradykinin B2 receptor, as an on-demand treatment for hereditary angioedema attacks. The firm thought shares would have moved higher on the outcome, as it views the data as very strong, combined with the validated market opportunity, as demonstrated by the strength in the Ekterly launch. This may be because investors focus primarily on the primary endpoint magnitude, although, Leerink believes that this is just one point of potential differentiation. The firm further thinks the HAE market is large enough for multiple players, especially as it continues to expand with the approval of new options.

Morgan Stanley

Maxwell Skor

Overweight

maintain

$37 -> $41

2025-12-03

Reason

Morgan Stanley

Maxwell Skor

Price Target

$37 -> $41

2025-12-03

maintain

Overweight

Reason

Morgan Stanley analyst Maxwell Skor raised the firm's price target on Pharvaris to $41 from $37 and keeps an Overweight rating on the shares. With RAPIDe-3, the firm sees confirmation of a differentiated, rapid, and durable oral on-demand profile. The firm added that it expects investor focus to shift now to the planned NDA submission in 1H26 and the pivotal prophylactic data readout expected in 2H26.

BofA

Neutral

maintain

$27 -> $30

2025-12-03

Reason

BofA

Price Target

$27 -> $30

2025-12-03

maintain

Neutral

Reason

BofA raised the firm's price target on Pharvaris to $30 from $27 and keeps a Neutral rating on the shares. The company reported positive topline results for the Phase 3 RAPIDe-3 study, with the study meeting its primary endpoint, the analyst tells investors in a research note. The firm thinks additional upside will likely be contingent on positive phase 3 results for decuri' XR in prophylactic HAE.

Morgan Stanley

Overweight

maintain

$34 -> $37

2025-11-13

Reason

Morgan Stanley

Price Target

$34 -> $37

2025-11-13

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Pharvaris to $37 from $34 and keeps an Overweight rating on the shares. The company continues to anticipate topline data from the pivotal Phase RAPIDe-3 trial of deucrictibant for the on-demand treatment of hereditary angioedema attacks in Q4, which represents a meaningful near-term catalyst, the analyst tells investors in a research note.

H.C. Wainwright

NULL

Buy

initiated

$60

2025-10-15

Reason

H.C. Wainwright

Price Target

$60

2025-10-15

initiated

NULL

Buy

Reason

H.C. Wainwright initiated coverage of Pharvaris with a Buy rating and $60 price target. The company's lead asset deucrictibant is the only oral bradykinin B2 receptor antagonist in development across both on-demand and prophylaxis settings, the analyst tells investors in a research note. The firm says deucrictibant is positioned to set a new standard in hereditary angioedema on-demand and prophylaxis.

Citizens JMP

Outperform

NULL

downgrade

$55 -> $52

2025-08-13

Reason

Citizens JMP

Price Target

$55 -> $52

2025-08-13

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Pharvaris to $52 from $55 and keeps an Outperform rating on the shares. Pharvaris continues to execute on its pivotal hereditary angioedema programs with data from its pivotal RAPIDe-3 trial in acute HAE in Q4 and CHAPTER-3 data in HAE prophylaxis in the second half of 2026, the analyst tells investors in a research note. The firm is impressed with management's execution with the first Phase 3 data for deucrictibant for on-demand HAE treatment expected next quarter.

Valuation Metrics

The current forward P/E ratio for Pharvaris NV (PHVS.O) is -8.65, compared to its 5-year average forward P/E of -6.91. For a more detailed relative valuation and DCF analysis to assess Pharvaris NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.91

Current PE

-8.65

Overvalued PE

-4.39

Undervalued PE

-9.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.53

Current EV/EBITDA

-6.28

Overvalued EV/EBITDA

-1.67

Undervalued EV/EBITDA

-7.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PHVS News & Events

Events Timeline

No data

News

4.0

2025-12-06NASDAQ.COM

Pharvaris N.V. (PHVS) Price Target Raised by 20.90% to $45.73

4.5

2025-12-03NASDAQ.COM

Stocks Rise on Hope for Fed Rate Cuts

4.5

2025-12-03NASDAQ.COM

Stocks Bounce Back Amid Anticipation of Fed Rate Cuts

People Also Watch

Frequently Asked Questions

What is Pharvaris NV (PHVS) stock price today?

The current price of PHVS is 25.89 USD — it has increased 3.56 % in the last trading day.

What is Pharvaris NV (PHVS)'s business?

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

What is the price predicton of PHVS Stock?

What is Pharvaris NV (PHVS)'s revenue for the last quarter?

Pharvaris NV revenue for the last quarter amounts to -39.66M USD, increased 4.65 % YoY.

What is Pharvaris NV (PHVS)'s earnings per share (EPS) for the last quarter?

Pharvaris NV. EPS for the last quarter amounts to -30687627.00 USD, decreased -8.58 % YoY.

What changes have occurred in the market's expectations for Pharvaris NV (PHVS)'s fundamentals?

The market is revising No Change the revenue expectations for PHVS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 13.35%.

How many employees does Pharvaris NV (PHVS). have?

Pharvaris NV (PHVS) has 82 emplpoyees as of January 10 2026.

What is Pharvaris NV (PHVS) market cap?

Today PHVS has the market capitalization of 1.68B USD.